This article is more than 5 years old. Information may no longer be current.

VIDEO: Intra-articular sprifermin prevented cartilage loss in patients with knee OA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Marc C. Hochberg, MD, spoke about a study that evaluated the efficacy and safety of intra-articular sprifermin in patients with symptomatic radiographic knee osteoarthritis. When sprifermin was administered at a higher dose at 6 months or 12 months it slowed progression of joint space loss or cartilage thinning and was associated with an increase in cartilage thickness.